drugset / Trial / NCT02681978

Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease

NCT02681978

Phase 4 Completed 70 enrolled Campus-Bio-Medico University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the effect of ivabradine on endothelial function in patients with coronary artery disease (CAD) after complete revascularization with percutaneous coronary angioplasty (PCI). At least 30 days after PCI, patients will be randomized to receive ivabradine 5 mg twice daily or to continue with standard medical therapy.

Timeline

Start
2014-02
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ivabradine Small molecule 5 mg
Comparator Ivabradine Small molecule 7.5 mg